Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
30.79%
Operating Margin
-126.22%
Net Margin
156.32%
Efficiency Metrics
Revenue per Expense Ratio
0.64
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
193.80%
Income Tax Rate
0.00%
EPS
1.9300000000
Balance Sheet Analysis
Current Ratio
0.00
Cash Ratio
0.02
Working Capital
$-501.81M
Debt to Equity
0.45
Debt to Assets
30.82%
Equity Ratio
68.67%
Cash Flow Analysis
Operating Cash Flow Ratio
81.19%
Free Cash Flow Ratio
81.19%
CapEx to Revenue
0.00%
Dividends Paid
$71.97M
Stock Buybacks
No buybacks
Total Shareholder Returns
$71.97M
Cash Position Change
-99.45%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
119.11%
Net Income
129.85%
EPS
129.07%
Operating Income
75.17%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
29.30%
Operating Cash Flow
-74.99%
Free Cash Flow
-74.99%
Balance Sheet Health
Assets
-0.71%
Debt
-11.19%
Book Value per Share
1.88%
Inventory
0.00%
Shareholder Returns
Dividends per Share
-19.70%
Shares Outstanding
2.53%
Long Term Trends
3Y Revenue/Share
-35.04%
5Y Revenue/Share
-54.51%
3Y Dividend/Share
100.45%
5Y Dividend/Share
-17.89%